What does L - PHARMA do?

L - PHARMA is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 14 December 1994, 1 establishment.

What is the address of L - PHARMA?

The registered office of L - PHARMA is located at Lindekensstraat 31 box 1, 2300 Turnhout.

Is L - PHARMA still active?

Yes. According to the CBE (31 October 2026) L - PHARMA is active, legal situation “Normale toestand”, started on 14 December 1994.

Is L - PHARMA registered on Peppol?

Yes, L - PHARMA is registered on the Peppol network with ID 0208:0453967027.

What is the enterprise number of L - PHARMA?

The enterprise number of L - PHARMA is BE0453967027.

When was L - PHARMA founded?

L - PHARMA was founded on 14 December 1994.

Who are the directors of L - PHARMA?

According to the 2025 annual accounts, the directors of L - PHARMA are: Patrick Lenaerts.

Is L - PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 December 1994; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did L - PHARMA make in 2025?

L - PHARMA recorded a loss after taxes of € 3,853 in financial year 2025.

What is the revenue of L - PHARMA?

As a small company, L - PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -3,714.

L - PHARMA (Public Limited) - Turnhout - BE0453967027

Dossier L - PHARMA, printed on 31 October 2026 from databakkes.be/en/0453967027/l-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

L - PHARMA from Turnhout, company number BE0453967027, closed financial year 2025 with a result of € -3,853 after tax. For that financial year L - PHARMA recorded a gross margin of € -3,714 and equity of € -509,185. Compared with financial year 2024, the result moved from € -1,613 to € -3,853. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Caution

€ -509,185

▼ € 3,853 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3,853

▼ 139 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 10

▼ 90% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -583,553.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

€ 500,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2,013

▲ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 1,077 Gross margin 2022: € 1,077 First fiscal year in the series	€ 298 Gross margin 2023: € 298 ▼ 72% vs 2022 (€ 1,077) Unfavourable step	€ -1,294 Gross margin 2024: € -1,294 ▼ € 1,591 vs 2023 (€ 298) Unfavourable step	€ -3,714 Gross margin 2025: € -3,714 ▼ € 2,421 vs 2024 (€ -1,294) Unfavourable step	▼ € 2,421
Profit after taxes	€ 720 Profit after taxes 2022: € 720 First fiscal year in the series	€ -68 Profit after taxes 2023: € -68 ▼ € 788 vs 2022 (€ 720) Unfavourable step	€ -1,613 Profit after taxes 2024: € -1,613 ▼ € 1,545 vs 2023 (€ -68) Unfavourable step	€ -3,853 Profit after taxes 2025: € -3,853 ▼ € 2,239 vs 2024 (€ -1,613) Unfavourable step	▼ € 2,239
Equity	€ -503,651 Equity 2022: € -503,651 First fiscal year in the series	€ -503,719 Equity 2023: € -503,719 Unchanged (€ -503,651) Unfavourable step	€ -505,332 Equity 2024: € -505,332 Unchanged (€ -503,719) Unfavourable step	€ -509,185 Equity 2025: € -509,185 ▼ € 3,853 vs 2024 (€ -505,332) Unfavourable step	▼ € 3,853
Total debts	€ 504,261 Total debts 2022: € 504,261 First fiscal year in the series	€ 504,208 Total debts 2023: € 504,208 Unchanged (€ 504,261) Favourable step	€ 505,428 Total debts 2024: € 505,428 Unchanged (€ 504,208) Unfavourable step	€ 509,194 Total debts 2025: € 509,194 ▲ 1% vs 2024 (€ 505,428) Unfavourable step	▲ 1%
Cash	€ 17 Cash 2022: € 17 First fiscal year in the series	€ 166 Cash 2023: € 166 ▲ € 149 vs 2022 (€ 17) Favourable step	€ 96 Cash 2024: € 96 ▼ 42% vs 2023 (€ 166) Unfavourable step	€ 10 Cash 2025: € 10 ▼ 90% vs 2024 (€ 96) Unfavourable step	▼ 90%
Retained profit	€ -578,019 Retained profit 2022: € -578,019 First fiscal year in the series	€ -578,087 Retained profit 2023: € -578,087 Unchanged (€ -578,019) Unfavourable step	€ -579,700 Retained profit 2024: € -579,700 Unchanged (€ -578,087) Unfavourable step	€ -583,553 Retained profit 2025: € -583,553 ▼ € 3,853 vs 2024 (€ -579,700) Unfavourable step	▼ € 3,853
Bank debt	€ 500,000 Bank debt 2022: € 500,000 First fiscal year in the series	€ 500,000 Bank debt 2023: € 500,000 Unchanged (€ 500,000) Unchanged	€ 500,000 Bank debt 2024: € 500,000 Unchanged (€ 500,000) Unchanged	€ 500,000 Bank debt 2025: € 500,000 Unchanged (€ 500,000) Unchanged
Balance sheet total	€ 610 Balance sheet total 2022: € 610 First fiscal year in the series	€ 489 Balance sheet total 2023: € 489 ▼ 20% vs 2022 (€ 610) Unchanged	€ 96 Balance sheet total 2024: € 96 ▼ 80% vs 2023 (€ 489) Unchanged	€ 10 Balance sheet total 2025: € 10 ▼ 90% vs 2024 (€ 96) Unchanged	▼ 90%

Key figures of L - PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to L - PHARMA?

What happened at L - PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 31, 2026 New annual accounts for financial year 2025: loss of € 3,853. Source: NBB ↗
Dec 21, 1994 New establishment in Turnhout. KBO
Dec 14, 1994 Start of the company according to the CBE. KBO

In short

From € 720 profit in 2022 to € 3,853 loss in 2025.

Best year ever: 2022, with € 720 profit.

Original PDFs at the National Bank ↗

Management

Patrick Lenaerts

L - PHARMA

Behind L - PHARMA is Patrick Lenaerts.

Directors

According to the 2025 annual accounts

Patrick Lenaerts

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Lindekensstraat 31 box 1

2300 Turnhout

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0453.967.027

VAT number

BE 0453.967.027

Registered office

Lindekensstraat 31 bus 1, 2300 Turnhout

Names & denominations

L - PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

14 December 1994

Peppol

Active · Active since 19 Sept 2025

Activities · NACE

Vervaardiging van geneesmiddelen

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

L - PHARMA

Warning lights

Financials

What happened to L - PHARMA?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions